Novo Nordisk is using its knowledge of protein chemistry, understanding of hormones and disease insight to develop efficient treatments for people with obesity. Obesity can have many serious health consequences, including type 2 diabetes, heart disease, high blood pressure, obstructive sleep apnoea and many types of cancer.
Obesity is defined as abnormal or excessive fat accumulation that may impair health for people with a body mass index (BMI) of more than 30. Healthy eating and physical activity must be part of any weight loss intervention, but this is not always sufficient to maintain weight loss. The body is pre-programmed to fight weight loss as a natural defence in a famine-like situation. So when someone eats less, their metabolism will slow down and the brain will subconsciously increase hunger signals.
To help people achieve meaningful and sustainable weight loss, Novo Nordisk is focusing on developing novel treatments that suppress energy intake and increase energy expenditure. These new treatments will allow some people to better control their appetite and will increase their metabolism. Our aim is to reduce the risks of certain comorbidities associated with obesity, and thereby improve the health and quality of life of people living with obesity.
Every year, we conduct clinical trials in more than 50 countries. To ensure best practice, skills and knowledge in the development of therapies, we work with the world's leading academic centres and preferred industrial partners. An overview of these activities worldwide can be found on our clinical trials website.